257 related articles for article (PubMed ID: 34389971)
21. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
[TBL] [Abstract][Full Text] [Related]
22. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
[TBL] [Abstract][Full Text] [Related]
23. Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen.
Wurster CD; Koch JC; Cordts I; Dreyhaupt J; Otto M; Uzelac Z; Witzel S; Winter B; Kocak T; Schocke M; Weydt P; Wollinsky K; Ludolph AC; Deschauer M; Lingor P; Tumani H; Hermann A; Günther R
Front Neurol; 2019; 10():1179. PubMed ID: 31787927
[No Abstract] [Full Text] [Related]
24. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
[TBL] [Abstract][Full Text] [Related]
25. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy.
Pera MC; Coratti G; Bovis F; Pane M; Pasternak A; Montes J; Sansone VA; Dunaway Young S; Duong T; Messina S; Mizzoni I; D'Amico A; Civitello M; Glanzman AM; Bruno C; Salmin F; Morando S; De Sanctis R; Sframeli M; Antonaci L; Frongia AL; Rohwer A; Scoto M; De Vivo DC; Darras BT; Day J; Martens W; Patanella KA; Bertini E; Muntoni F; Finkel R; Mercuri E;
Ann Clin Transl Neurol; 2021 Aug; 8(8):1622-1634. PubMed ID: 34165911
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
[TBL] [Abstract][Full Text] [Related]
27. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
[TBL] [Abstract][Full Text] [Related]
28. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
30. Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen.
Vidovic M; Freigang M; Aust E; Linse K; Petzold D; Günther R
BMC Neurol; 2023 Jun; 23(1):216. PubMed ID: 37280513
[TBL] [Abstract][Full Text] [Related]
31. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.
Wurster CD; Günther R; Steinacker P; Dreyhaupt J; Wollinsky K; Uzelac Z; Witzel S; Kocak T; Winter B; Koch JC; Lingor P; Petri S; Ludolph AC; Hermann A; Otto M
Ther Adv Neurol Disord; 2019; 12():1756286419846058. PubMed ID: 31205491
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
[TBL] [Abstract][Full Text] [Related]
33. Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Steinbach M; Blaschek A; Baumann M; Baumgartner M; Becker B; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Küpper H; Johannsen J; Kamm C; Koch JC; Köhler C; Kölbel H; Kolzter K; von Moers A; Naegel S; Neuwirth C; Petri S; Rödiger A; Schimmel M; Schrank B; Schreiber G; Smitka M; Stadler C; Steiner E; Stögmann E; Trollmann R; Türk M; Weiler M; Stoltenburg C; Willichowsky E; Zeller D; Ziegler A; Lochmüller H; Kirschner J;
J Neuromuscul Dis; 2023; 10(1):29-40. PubMed ID: 36565133
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures.
Kessler T; Sam G; Wick W; Weiler M
Eur J Neurol; 2024 Jan; 31(1):e16099. PubMed ID: 37823715
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal Assessment of Timed Function Tests in Ambulatory Individuals with SMA Treated with Nusinersen.
Krosschell KJ; Brown L; Hoffman K; Zumpf KB; Munson H; Bidwell J; Schulte DP; Schwaede AN; Buehner AN; DiDonato CJ; Kuntz NL; Rao VK
J Neuromuscul Dis; 2023; 10(3):337-348. PubMed ID: 36872785
[TBL] [Abstract][Full Text] [Related]
36. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy.
Stolte B; Bois JM; Bolz S; Kizina K; Totzeck A; Schlag M; Kleinschnitz C; Hagenacker T
Eur J Neurol; 2020 Dec; 27(12):2586-2594. PubMed ID: 32781490
[TBL] [Abstract][Full Text] [Related]
37. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
Seo G; Kim S; Byun JC; Kwon S; Lee YJ
Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
[TBL] [Abstract][Full Text] [Related]
39. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.
Jiang Y; Wang Y; Xiong H; Li W; Luo R; Chen W; Yin F; Lü J; Liang J; Chen WJ; Lu X; Wang H; Tang J; Monine M; Makepeace C; Jin X; Foster R; Chin R; Berger Z
Adv Ther; 2024 Jul; 41(7):2743-2756. PubMed ID: 38722537
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy.
Sarıkaya Uzan G; Paketçi C; Günay Ç; Edem P; Özsoy Ö; Hız Kurul S; Yiş U
Neuropediatrics; 2022 Oct; 53(5):321-329. PubMed ID: 35871521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
